MitoImmune Therapeutics
PrivateLast Round
Series B
Extension
Sep 25, 2023
Total Funding Raised
$38.81M
Company Overview
MitoImmune Therapeutics is a biotechnology company that develops innovative drugs targeting mitochondrial dysfunction and regulated necrotic cell death.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MitoImmune Therapeutics Comparables
Compare MitoImmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Morningside | 78% | |
| SeaBeLife | 77% | |
| Pretzel Therapeutics | 77% |
MitoImmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 25, 2023 | ||||
| Series B | Feb 26, 2021 | ||||
| Series A | Apr 1, 2019 |
MitoImmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BNH INVESTMENT | Series A, Series B |
| SL Investment | Series A, Series B |
| KB Investment | Series A, Series B |
| Orion Capital Management | Series B |
| K-Ground Ventures | Series B Extension |
| GTO Investment | Series B |
| CJ Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Monthly visitors increased 56% MoM.
- Jan 7, 2026
Monthly visitors grew 347% MoM, reaching 1.9K.
MitoImmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MitoImmune Therapeutics's valuation, stock price, and market status.
Is MitoImmune Therapeutics a public or private company?
MitoImmune Therapeutics is a private company.
What is the current stock price of MitoImmune Therapeutics?
MitoImmune Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is MitoImmune Therapeutics worth (valuation)?
Valuation information for MitoImmune Therapeutics is not publicly available.
Can I buy MitoImmune Therapeutics stock?
MitoImmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MitoImmune Therapeutics's last funding round?
MitoImmune Therapeutics's most recent funding round was Series B Extension on September 25, 2023.
Who are the main investors in MitoImmune Therapeutics?
Key investors in MitoImmune Therapeutics include Korea Development Bank.
Will MitoImmune Therapeutics IPO soon?
No public IPO plans have been announced for MitoImmune Therapeutics.
How can I track MitoImmune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MitoImmune Therapeutics's secondary market activity and sign up for updates.